{
  "filename": "Brown et al. - 2020 - Pediatric acute lymphoblastic leukemia, version 2.2020-annotated.pdf",
  "total_citations": 3,
  "unique_references": 2,
  "citations": [
    {
      "text": "(1)",
      "context": "the frontline and relapsed/refractory management of pediatric ALL.\n\n> J Natl Compr Canc Netw 2020;18(1):81\u2013112 doi: 10.6004/jnccn.2020.0001\n\n1 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopki",
      "citation_type": "numeric",
      "position": {
        "start": 1505,
        "end": 1508
      },
      "normalized_text": "1"
    },
    {
      "text": "(1)",
      "context": "ic and AYA patients with Ph-negative ALL in CR1, allogeneic HSCT may be considered for patients who (1) remain MRD positive at the end of consolidation (regardless of genetic features); or (2) have high-",
      "citation_type": "numeric",
      "position": {
        "start": 53734,
        "end": 53737
      },
      "normalized_text": "1"
    },
    {
      "text": "(2)",
      "context": "tients who (1) remain MRD positive at the end of consolidation (regardless of genetic features); or (2) have high-risk genetic features and are MRD-positive at EOI.141 In the latter group, it should be n",
      "citation_type": "numeric",
      "position": {
        "start": 53823,
        "end": 53826
      },
      "normalized_text": "2"
    }
  ],
  "unique_reference_ids": [
    "1",
    "2"
  ]
}